In this article
Introduction
A Queensland University of Technology (QUT) researcher is developing a simple saliva test to detect human papillomavirus (HPV) in laryngeal cancer. This is an extension of cooperation with Johnson & Johnson, Jensen Vaccine Prevention, and Jensen Sidip Ltd.
Test
A Queensland University of Technology (QUT) researcher is developing a simple saliva test to detect human papillomavirus (HPV) in laryngeal . This is an extension of cooperation with Johnson & Johnson, Jensen Vaccine Prevention, and Jensen Sidip Ltd.
Professor Chamindie Punyadeera from the QUT Institute of Health and Biomedical Innovation (IHBI) said that with the development of new therapeutic vaccines, it is important to identify those in the general population who should receive vaccine treatment. In the early stages of HPV-induced laryngeal cancer, identifying high-risk groups will help prevent cancer from worsening.
Highly sensitive diagnosis based on saliva provides a possibility to detect human HPV infection in a low-cost, non-invasive way.
The new therapeutic is expected to have an immediate impact on the prevalence of HPV-related malignancies.
Professor Punyadeera said HPV has proven to be more difficult to identify than cancers caused by smoking.
She said the goal of the new technology is to identify people who are at risk for laryngeal cancer and intercept them before they develop symptoms such as sore throat, difficulty swallowing, or a lump in the neck or throat.
This way, diagnosis and early treatment can begin before invasive treatment is required.
Punyadeera’s research has developed a diagnostic saliva flush test that can help general practitioners, oncologists, and dentists to detect early-stage throat cancer. We hope that a simple, non-invasive saliva sample will be sent to the laboratory or field test to determine whether the patient needs further examination.
Professor Punyadeera said: Ultimately, we hope to develop a test that allows patients to perform home tests and monitoring.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Related Topics
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.